A Clinical Prognostic Score to Predict Survival of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy: A Retrospective Analysis

Jing Gong(Shandong University), Xiujuan Qu(First Hospital of China Medical University), Xiaonan Shi(First Hospital of China Medical University), Ling Xu(Xinyang Central Hospital), Jing Shi(Singapore Institute of Technology), Yuee Teng(First Hospital of China Medical University), Mingfang Zhao(First Hospital of China Medical University), Xuejun Hu(Zoucheng People's Hospital), Jing Liu(Central South University), Zhi Li(New York University), Bo Jin, Yu Cheng(Hebei University), Yunpeng Liu(Shenyang Institute of Automation), Tianshu Guo(Ministry of Education of the People's Republic of China)
Medical Science Monitor
November 17, 2018
10.12659/msm.911026
Cited by 13

Related Papers

The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508